Adcist 50mg Injection

Testicular tumor
Ovarian tumor
Bladder tumor
Lung cancer
Head and neck epithelial tumor
Cervical cancer

Undesired symptoms or responses vary from person to person as the human body reacts differently to the Adcist 50 Injection, but they typically resolve naturally within a few days as the body adjusts to the medicine, requiring no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Adcist 50 Injection are: Fatigue Headache Fever loss of appetite Nausea Low blood count hair loss Diarrhea or constipation

Adacist 50 Injection is given slowly in the veins; it is generally advised to receive lots of water before and after the injection to protect the kidneys. Do not use the same injection or syringe for another injection, as there is a chance of interaction. Always check the vial of injection before using it for discoloration or any kind of particulate matter, and shake well for uniform mixing of the product. Adcist 50 Injection is administered once every 3-4 weeks or for 5 consecutive days. Always consult your doctor before taking the vaccine, especially if you have a family history of blood disorders, heart problems, lung problems, pain in the limbs, or kidney problems.

Cisplatin, which is present in the Adcist 50 injection, cross-links with the DNA, and it damages the DNA (genetic material) present in the cancer cells. After the drug enters cells, it forms a strong bond with the DNA, preventing the cancer cells from synthesizing or copying their genetic material, hence stopping the growth and division of cancer cells.

Desoize, B., & Madoulet, C. (2022). Particular aspects of platinum compounds are used at present in cancer treatment. Critical reviews in oncology/hematology, 42(3), 317-325.

Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2021). Novel metals and metal complexes as platforms for cancer therapy. Current pharmaceutical design, 16(16), 1813-1825.


Mrdenovic, S., Wang, Y., Yin, L., Chu, G. C. Y., Ou, Y., Lewis, M. S., & Zhang, Y. (2023). A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer models. BMC cancer, 23(1), 499.


Nagai, H., & Kim, Y. H. (2025). Cancer prevention from the perspective of global cancer burden patterns. Journal of Thoracic Disease, 9(3), 448.


Ranasinghe, R., Mathai, M. L., & Zulli, A. (2022). Cisplatin for cancer therapy and overcoming chemoresistance. Heliyon, 8(9).